-
13:00
-13:07
BRCA2 non-ovarian cancer cluster region mutations and prognosis of first-line PARP inhibitor maintenance therapy: a multicenter retrospective nomogram study in Chinese population
-
13:07
-13:14
BRCA1/2 synonymous variants are associated with favorable outcomes to PARP inhibitor maintenance in ovarian cancer
-
13:14
-13:21
Shared and site-specific molecular features of cervical, endometrial, and ovarian clear cell carcinomas
-
13:21
-13:28
Integrated deconvolution of plasma cell-free RNA reveals immune and tissue‑origin signatures linked to clinical parameters in gynecological cancers
-
13:28
-13:35
Non-invasive prediction of BRCA mutation status in ovarian cancer using whole-body tumor burden deep learning: a novel pathway towards precision medicine and accessible genetic testing
-
13:35
-13:42
A non-invasive three-gene cfDNA methylation panel for the early detection of epithelial ovarian cancer: development and independent validation
-
13:42
-13:49
FDR-controlled serum metabolic fingerprints encode ovarian cancer diagnosis
-
13:49
-13:56
Development and validation of a screening model for ovarian cancer based on exhaled breath volatile organic compounds

